Skip to content

Nuvation Bio NUVB Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$199M+15.7%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$99K-28.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$13M+8.3%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$487K+29.2%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$350K+13.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$7.63M+2.2%

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's operating lease liabilities (current)?
Nuvation Bio (NUVB) reported operating lease liabilities (current) of $1.84M in Q1 2026.
How has Nuvation Bio's operating lease liabilities (current) changed year-over-year?
Nuvation Bio's operating lease liabilities (current) decreased by 2.7% year-over-year, from $1.89M to $1.84M.
What is the long-term trend for Nuvation Bio's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Nuvation Bio's operating lease liabilities (current) has grown at a 13.5% compound annual growth rate (CAGR), from $1M to $1.88M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.